{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:39:19Z","timestamp":1783690759316,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Paclitaxel (PTX) is an antineoplastic drug widely used in treatments for ovarian, breast, and small-cell lung cancer. Although ocular effects associated with PTX have been previously described, very few studies have specifically reported systemic PTX as a contributing factor for limbal stem cell deficiency (LSCD), which is characterized by the loss of stem cell and barrier function of the limbus leading to progressive pain and reduction in visual acuity. Described here is a unique case where a patient was diagnosed with LSCD secondary to PTX use for the treatment of breast cancer, at doses of PTX far lower than what is reported in current literature.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 73-year-old woman with a previous diagnosis of breast cancer with liver metastasis presented with a complaint of increasing pain in the left eye more than the right, along with decreasing visual acuity in both eyes following 3\u00a0months of PTX therapy for recurrent liver metastases. Upon examination, best-corrected visual acuity was 20\/100 in the right eye and counting fingers on the left. Peripheral neovascularization, stromal scarring, and features of limbal stem cell deficiency (LSCD) were noted on the right cornea. A central neurotrophic ulcer with thinning to 50% and 360 degrees of conjunctivalization were noted on the left. After the discontinuation PTX with doxorubicin as the substitute, there was no further progression of her LSCD, and stabilization of her ocular surface was achieved.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Although chemotherapy induced LSCD is a relatively rare adverse event, it is essential for clinicians starting new chemotherapy agents to consider the potential ocular toxicities that may result in their use. Ophthalmology review is recommended for patients after starting PTX therapy to assess for signs of LSCD, particularly in patients where drug toxicity can be aggravated due to impaired hepatic function.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12886-020-01672-x","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T18:03:01Z","timestamp":1602093781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Limbal stem cell deficiency secondary to systemic paclitaxel (Taxol) for breast cancer: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Amardeep","family":"Sekhon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff Y. F.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnson C. H.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1197-8026","authenticated-orcid":false,"given":"Sonia N.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"issue":"2","key":"1672_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5966\/sctm.2011-0037","volume":"1","author":"S Ahmad","year":"2012","unstructured":"Ahmad S. Concise review: limbal stem cell deficiency, dysfunction, and distress. Stem Cells Transl Med. 2012;1(2):110\u20135.","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"1672_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1159\/000477897","volume":"10","author":"T Yokoe","year":"2017","unstructured":"Yokoe T, Fukada I, Kobayashi K, Shibayama T, Miyagi Y, Yoshida A, et al. Cystoid macular edema during treatment with paclitaxel and Bevacizumab in a patient with metastatic breast Cancer: a case report and literature review. Case Rep Oncol. 2017;10(2):605\u201312.","journal-title":"Case Rep Oncol"},{"issue":"2","key":"1672_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3892\/mco.2017.1296","volume":"7","author":"E Bassi","year":"2017","unstructured":"Bassi E, Loizzi V, Furino C, Martino R, Alessio G, Ettore C, et al. Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: a case report. Mol Clin Oncol. 2017;7(2):285\u20137.","journal-title":"Mol Clin Oncol"},{"issue":"10","key":"1672_CR4","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/OPX.0000000000000945","volume":"93","author":"HS Lee","year":"2016","unstructured":"Lee HS, Ha JY, Choi W, Yoon KC. Bilateral corneal epithelial lesions associated with paclitaxel. Optom Vis Sci. 2016;93(10):1333\u20136.","journal-title":"Optom Vis Sci"},{"issue":"8","key":"1672_CR5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.eye.6700616","volume":"17","author":"S Bonini","year":"2003","unstructured":"Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. Eye (Lond). 2003;17(8):989\u201395.","journal-title":"Eye (Lond)"},{"issue":"3","key":"1672_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/bjo.85.3.371c","volume":"85","author":"P Ellies","year":"2001","unstructured":"Ellies P, Anderson DF, Topuhami A, Tseng SC. Limbal stem cell deficiency arising from systemic chemotherapy. Br J Ophthalmol. 2001;85(3):373\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"1672_CR7","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ajo.2003.10.048","volume":"137","author":"BW Dudney","year":"2004","unstructured":"Dudney BW, Malecha MA. Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia. Am J Ophthalmol. 2004;137(5):950\u20131.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1672_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/ICO.0b013e318183a3bd","volume":"28","author":"X Ding","year":"2009","unstructured":"Ding X, Bishop RJ, Herzlich AA, Patel M, Chan CC. Limbal stem cell deficiency arising from systemic chemotherapy with hydroxycarbamide. Cornea. 2009;28(2):221\u20133.","journal-title":"Cornea."},{"issue":"3","key":"1672_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/00003226-200005000-00005","volume":"19","author":"RT Pires","year":"2000","unstructured":"Pires RT, Chokshi A, Tseng SC. Amniotic membrane transplantation or conjunctival limbal autograft for limbal stem cell deficiency induced by 5-fluorouracil in glaucoma surgeries. Cornea. 2000;19(3):284\u20137.","journal-title":"Cornea."},{"key":"1672_CR10","volume-title":"Limbal epithelial stem cells of the cornea","author":"GA Secker","year":"2008","unstructured":"Secker GA, Daniels JT. Limbal epithelial stem cells of the cornea. Cambridge: Harvard Stem Cell Institute Copyright: \u00a9 2009 Genevieve A. Secker and Julie T. Daniels: StemBook; 2008."},{"key":"1672_CR11","unstructured":"Katzung B, Masters S, Trevor A. Cancer Chemotherapy. London: In: Basic and Clinical Pharmacology: McGraw-Hill Medical; 2009. p. 935\u2013962."},{"issue":"5","key":"1672_CR12","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1200\/JCO.1998.16.5.1811","volume":"16","author":"AP Venook","year":"1998","unstructured":"Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and leukemia group B 9264. J Clin Oncol. 1998;16(5):1811\u20139.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1672_CR13","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver BA. How Taxol\/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25(18):2677\u201381.","journal-title":"Mol Biol Cell"},{"issue":"1","key":"1672_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40262-017-0563-z","volume":"57","author":"TB Stage","year":"2018","unstructured":"Stage TB, Bergmann TK, Kroetz DL. Clinical pharmacokinetics of paclitaxel Monotherapy: an updated literature review. Clin Pharmacokinet. 2018;57(1):7\u201319.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1672_CR15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/IJG.0b013e31815c89b9","volume":"16","author":"OG Koz","year":"2007","unstructured":"Koz OG, Ozhuy S, Tezel GG, Karaman N, Unlu N, Yarangumeli A, et al. The effect of paclitaxel on conjunctival wound healing: a pilot study. J Glaucoma. 2007;16(7):610\u20135.","journal-title":"J Glaucoma"},{"key":"1672_CR16","first-page":"1361","volume":"7","author":"Y Li","year":"2014","unstructured":"Li Y, Li Y, Li J, Pi G, Tan W. Paclitaxel- and\/or cisplatin-induced ocular neurotoxicity: a case report and literature review. Onco Targets Ther. 2014;7:1361\u20136.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"1672_CR17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3341\/kjo.2012.26.5.388","volume":"26","author":"DS Ham","year":"2012","unstructured":"Ham DS, Lee JE, Kim HW, Yun IH. A case of cystoid macular edema associated with paclitaxel chemotherapy. Korean J Ophthalmol. 2012;26(5):388\u201390.","journal-title":"Korean J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01672-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-020-01672-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01672-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T02:17:23Z","timestamp":1633573043000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01672-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1672"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01672-x","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"assertion":[{"value":"21 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"400"}}